ENDRA Life Sciences Inc (NDRA)

NASD · Healthcare · Diagnostics & Research · USA

ENDRA Life Sciences Inc is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.

ENDRA Life Sciences develops Thermo-Acoustic Enhanced Ultrasound (TAEUS), a next-generation ultrasound technology platform designed to assess liver fat content. The company's initial application targets diseases involving hepatic steatosis and inflammation. ENDRA serves pharmaceutical companies, clinical research organizations, concierge medicine networks, bariatric clinics, and primary care practices through a subscription-based model.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the ENDRA Life Sciences Inc stock.

Our verdict on NDRA

Not valued: We cannot value this company yet.

ETFs with the most weight in NDRA

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Cheaper than NDRA in Diagnostics & Research

23 more in this industry show a wider margin of safety.

Is NDRA undervalued or overvalued?

We do not publish a verdict on NDRA yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of NDRA?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.